NCT07044349 - Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Interventions

DRUG

Utidelone capsule 75mg/m2/d QD

75mg/m2/d, QD, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

DRUG

Utidelone capsule 40mg/m2/d BID

40mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

DRUG

Utidelone capsule 50mg/m2/d BID

50mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

DRUG

Utidelone capsule 35mg/m2/d BID

35mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.